NCT03558386 is a clinical trial of ePRO survey in Myelodysplastic Syndromes, sponsored by Center for International Blood and Marrow Transplant Research.

Who is sponsoring NCT03558386?

NCT03558386 is sponsored by Center for International Blood and Marrow Transplant Research.

What drugs are being tested in NCT03558386?

Interventions in NCT03558386: ePRO survey.

What condition does NCT03558386 study?

NCT03558386 studies Myelodysplastic Syndromes, Hematopoietic Cell Transplant.

Is NCT03558386 still recruiting?

NCT03558386 is currently completed. Last updated 2 December 2020.

Last reviewed 2020-12-02 · How we verify

NCT03558386

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes

Completed Last updated 2 December 2020

What this trial tests

trial testing ePRO survey in Myelodysplastic Syndromes in 92 participants. Completed in 15 November 2019.

Timeline

23 July 2018

Primary endpoint
15 November 2019

15 November 2019

Quick facts

Lead sponsor	Center for International Blood and Marrow Transplant Research
Status	Completed
Study type	OBSERVATIONAL
Enrollment	92
Start date	23 July 2018
Primary completion	15 November 2019
Estimated completion	15 November 2019
Sites	6 locations across United States

Drugs / interventions tested

ePRO survey

Conditions studied

Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
Hematopoietic Cell Transplant — all drugs for Hematopoietic Cell Transplant →

Sponsor

Center for International Blood and Marrow Transplant Research — full company profile →

Who can join

55 and older, any sex, with Myelodysplastic Syndromes or Hematopoietic Cell Transplant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myelodysplastic Syndromes

Currently open trials in the same condition.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06303193 — Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or · Phase 1, PHASE2 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
NCT07283900 — Ascorbate in Myelodysplastic Syndrome · Phase 2 · recruiting
NCT06487247 — HEME Home Transfusion Program · NA · recruiting

Other Center for International Blood and Marrow Transplant Research trials

Trials by the same sponsor.

NCT06001385 — HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cycloph · Phase 2 · active not recruiting
NCT05224661 — Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events · active not recruiting
NCT03992352 — Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704) · completed
NCT03904134 — Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) · NA · completed
NCT03718546 — Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03558386 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Center for International Blood and Marrow Transplant Research
Last refreshed: 2 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03558386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing